13 July 2021: British Patient Capital announces a follow-on investment to Quantexa, as the company announces the close of its Series D funding round at $153m. This latest fundraise follows a year of 108% growth for Quantexa during 2020/21, boosted by significant growth from new clients across geographies and industries. The round was led by Warburg Pincus.
Quantexa, a global data and analytics software company, connects billions of data points into a single contextual view to enable organisations to make better decisions. Its Contextual Decision Intelligence platform is used to detect financial crime, uncover risk, spot fraud and find new opportunities across banking, insurance, as well as other enterprises.
British Patient Capital first invested in Quantexa in its $64.7 million Series C round in July 2020. This was, as part as part of British Patient Capital’sa long-term co-investment strategy that identifies and supports high-potential, later-stage UK companies in its underlying portfolio. In the case of Quantexa, British Patient Capital had a prior exposure via its commitment to Dawn Capital’s third fund.
Judith Hartley, CEO, British Patient Capital said: “Quantexa is a great example of how patient capital, deployed at scale over multiple funding rounds can enable the accelerated growth of our high-potential innovative companies. This follow-on investment demonstrates British Patient Capital’s on-going commitment to Quantexa and the company’s continued future growth.”
Notes to Editors
About British Patient Capital
British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s commercial arm.
Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5bn to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at britishpatientcapital.co.uk.
British Business Bank plc and its principal operating subsidiaries are not banking institutions and do not operate as such. Neither British Business Bank nor its principal operating subsidiaries are authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.
British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.
The investment from British Patient Capital into Quantexa Limited does not amount to any endorsement or warranty from British Patient Capital, the British Business Bank plc, or the government of the UK.